PEPTIDE CORPUS

Cardiovascular & General

Irisin

Irisin is the closest thing there is to exercise in molecular form: when muscle works, it cuts this fragment loose from a larger membrane protein and releases it into the blood. In mice the fragment turns ordinary white fat into the heat-burning brown kind and rescues memory in Alzheimer's models, which is why it was seized on as a possible chemical link between training and metabolic health, and why the literature around it ran to thousands of papers within a decade of its discovery. The human record is entirely observational — blood levels compared against body composition, bone density, training programmes and disease states. No irisin-based product has ever entered a human clinical trial, so nothing on file says what taking it would do.

Last updated

Studied forAdipose browning research · Exercise metabolism marker · Bone metabolism context
Evidence on file4 human observational studies · 2 animal studies · 4 citations not yet graded
Strongest sourceFNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expr… (human observational study)

Mechanism

Muscle PGC-1alpha drives FNDC5 expression and irisin release, raising UCP1 in white adipocytes via MAPK signalling.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

  • Adipose browning research
  • Exercise metabolism marker
  • Bone metabolism context

Dosing on file unverified

No irisin-based therapeutic has entered human clinical trials as of 2026; in vitro: 5-100 ng/mL

Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.

Half-life, storage & sport

Elimination half-life
0.39 h, 0.3 h and 0.32 h at 100, 500 and 1000 ug/kg (mice) — study. Communications biology 2025; mice.

The half-life on file is 21 min, measured in mice. No dosing schedule could be read from this record, so the curve below is one dose drawn from the moment it is given. Nothing here says how often it is repeated.

One dose. 1.7 h of decay, normalised to its own peak.
1 compounds on one time axis, each normalised to its own peak0%25%50%75%100%0 min26 min52 min1.3 h1.7 hpeaktime from the first doseIrisin

The measurement is not human. It was made in mice, and small mammals clear peptides faster than people do — so this is the fastest plausible shape rather than the expected one.

The rise is not modelled and the axis is not a blood level. No absorption rate constant and no volume of distribution are on file, so each dose appears at full height the instant it is given, and the axis is percent of this compound's own peak.

Literature on file 11

Not graded

4 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

Notes unverified prose

Endogenous myokine; no therapeutic dosing; no FDA approval; No human clinical trials; preclinical

Not on file 9

8 of the 8 fields we track hold nothing on this record, and each says why. 1 further absence is named below. A blank field is a bug; a named absence is a finding.

Each field links to every other record missing the same thing. The full ledger holds 765 gaps across 163 records.